Background and Aims: Cardiac myxomas may present clinically with many different features. Since highly effective treatments exist, it is important that they are diagnosed quickly in order to avoid further complications. Our aim was to determine the influence of neurological presentation in diagnosis and prognosis of cardiac myxomas. Methods: We have reviewed the clinical charts of 28 patients diagnosed with cardiac myxomas seen at our centre in the last 20 years. Results: Mean age at diagnosis in patients with neurological events was 49.22 years and 60.84 years in those without neurological manifestations (p = 0.0325). Most frequent presentations were: cardiac manifestations (92.8%), general manifestations (71.4%) and embolic events (39.3%). Nine patients (32.1%) presented with cerebral embolism; 7 of whom presented with transient ischaemic attacks (TIA), which was the first manifestation in 6 of them; 3 of them later suffered complete cerebral infarction with sequelae. Echocardiography confirmed diagnosis in 26 out of 27 patients in which it was performed. None of the patients presented neurological symptoms after surgery. Conclusion: The most frequent initial neurological manifestation in our series was TIA. Nevertheless, none of the patients were diagnosed after the first neurological symptom. Although the contribution of cardiac myxomas to the total amount of TIA is low, since surgery is highly effective and of low risk, and patients with neurological manifestations are younger, it is vital to consider the possibility of cardiac myxoma after a TIA of unknown origin.

1.
Roberts WC: Primary and secondary neoplasms of the heart. Am J Cardiol 1997;80:671–682.
2.
Wold LE, Lie JT: Cardiac myxomas: A clinicopathologic profile. Am J Pathol 1980;101:219–240.
3.
McAllister HA Jr, Fenoglio JJ Jr: Tumours of the Cardiovascular System. Atlas of Tumour Pathology, series 2, Fascicle 15. Washington, Armed Forces Institute of Pathology, 1978, pp 1–20.
4.
Arboix A, Alvarez-Sabín J, Soler L: Ictus: Clasificación y criterios diagnósticos. Comité de Redacción ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN. Neurologia 1998;13(suppl 3):3–10.
5.
Feinberg WM, Albers GW, Barnett HJ, Biller J, Caplan LR, Carter LP, Hart RG, Hobson RW 2nd, Kronmal RA, Moore WS: Guidelines for the management of transient ischemic attacks. From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke 1994;25:1320–1335.
6.
Knepper LE, Biller J, Adams HP Jr, Bruno A: Neurologic manifestations of atrial myxoma. Stroke 1988;19:1435–1440.
7.
Shimono T, Makino S, Kanamori Y, Kinoshita T, Yada I: Left atrial myxomas. Using gross anatomic tumor types to determine clinical features and coronary angiographic findings. Chest 1995;107:674–679.
8.
Richardson JV, Brandt B 3rd, Doty DB, Ehrenhaft JL: Surgical treatment of atrial myxomas: Early and late results of 11 operations and review of the literature. Ann Thorac Surg 1979;28:354–358.
9.
Sandok BA, von Estorff I, Giuliani ER: CNS embolism due to atrial myxoma: Clinical features and diagnosis. Arch Neurol 1980;37:485–488.
10.
Markel ML, Waller BF, Armstrong WF: Cardiac myxoma. A review. Medicine (Baltimore) 1987;66:114–125.
11.
Bortolotti U, Maraglino G, Rubino M, Santini F, Mazzucco A, Milano A, et al: Surgical excision of intracardiac myxomas: A 20-year follow-up. Ann Thorac Surg 1990;49:449–453.
12.
Larsson S, Lepore V, Kennergren C: Atrial myxomas: Results of 25 years’ experience and review of the literature. Surgery 1989;105: 695–698.
13.
Robbin NA, Landless P, Cooper K, Fritz VU: Myxoma in the carotid artery. Myxomatous occlusion of internal carotid artery. Stroke 1997;28:456–458.
14.
Lacambra Blasco I, Capablo Liesa JL, Montori Lasilla M, Civera Val F, Ara Callizo JR, Alvarez Alegret R, et al: Deterioro mental como primera manifestación de un mixoma cardíaco. Rev Esp Neurol 1989; 4:371–374.
15.
Silverman J, Olwin JS, Graettinger JS: Cardiac myxomas with systemic embolisation: Review of the literature and report of a case. Circulation 1962;26:99–103.
16.
Hirose G, Kosoegawa H, Takado M, Shimazaki K, Murakami E: Spinal cord ischemia and left atrial myxoma. Arch Neurol 1979;36: 439.
17.
Symbas PN, Hatcher CR Jr, Gravanis MB: Myxoma of the heart: Clinical and experimental observations. Ann Surg 1976;183:470–475.
18.
MacGregor GA, Cullen RA: The syndrome of fever, anaemia and high sedimentation rate with an atrial myxoma. Br Med J 1959;5:158.
19.
St John Sutton MG, Mercier LA, Giuliani ER, Lie JT: Atrial myxomas: A review of clinical experience in 40 patients. Mayo Clin Proc 1980;55:371–376.
20.
Schmidley JW: Neurological presentations of atrial myxoma. Heart Dis Stroke 1993;2:483–486.
21.
Peters MN, Hall RJ, Cooley DA, Leachman RD, Garcia E: The clinical syndrome of atrial myxoma. JAMA 1974;230:695–701.
22.
Price DL, Harris JL, New PF, Cantu RC: Cardiac myxoma. A clinicopathologic and angiographic study. Arch Neurol 1970;23:558–567.
23.
Stoane L, Allen JH, Collins HA: Radiologic observations in cerebral embolisation from left heart myxoma. Radiology 1966; 87:262–266.
24.
Burton C, Johnston J: Multiple cerebral aneurysms and cardiac myxoma. N Engl J Med 1970;282:35–36.
25.
Damasio H, Seabra-Gomes R, da Silva JP, Damasio AR, Antunes JL: Multiple cerebral aneurysms and cardiac myxoma. Arch Neurol 1975;32:269–270.
26.
Desousa AL, Muller J, Campbell RL, Batnizky S, Rankin L: Atrial myxoma: A review of the neurological complications, metastases, and recurrences. J Neurol Neurosurg Psychiatry 1978;41:1119–1124.
27.
Reichmann H, Romberg-Hahnloser R, Hofmann E, Becker T, Mertens HG: Neurological long-term follow-up in left atrial myxoma: Are late complications frequent or rare? J Neurol 1992;239:170–174.
28.
Shyu KG, Chen JJ, Cheng JJ, Hwang JJ, Kuan P, Lien WP: Comparison of transthoracic and transesophageal echocardiography in the diagnosis of intracardiac tumors in adults. J Clin Ultrasound 1994;22:381–389.
29.
Asensio M, Campos A, Mainar A, Jiménez A: Mixoma auricular: Manifestaciones neurológicas. Rev Esp Neurol 1991;6:65–70.
30.
Zamorano J, Vilacosta I, Almeria C, San Roman JA, Castillo JA, Villanueva MA, Rollan MJ, Sanchez-Harguindey L: Aportaciones de la ecografía transesofágica en el diagnóstico y tratamiento de los mixomas cardíacos. Rev Esp Cardiol 1994;47:17–22.
31.
Rauh G, Fischereder M, Spengel F: Transesophageal echocardiography in patients with focal cerebral ischemia of unknown cause. Stroke 1996; 27:691–694.
32.
Lee RJ, Bartzokis T, Yeoh TK, Grogin HR, Choi D, Schnittger I: Enhanced detection of intracardiac sources of cerebral emboli by transesophageal echocardiography. Stroke 1991;22:734–739.
33.
Obeid AI, Marvasti M, Parker F, Rosenberg J: Comparison of transthoracic and transesophageal echocardiography in diagnosis of left atrial myxoma. Am J Cardiol 1989;63:1006–1008.
34.
Thomas KE, Winchell CP, Varco RL: Diagnostic and surgical aspects of left atrial tumors. J Thorac Cardiovasc Surg 1967;53:535–548.
35.
Malergue MC, Laurenceau JL, Dumesnill JG, Desaulniers D: Le myxoma auriculaire gauche: Une urgence chirurgicale. A propos de deux observations. Arch Mal Coeur 1977;70:93–97.
36.
McCarthy PM, Piehler JM, Schaff HV, Pluth JR, Orszulak TA, Vidaillet HJ Jr, Carney JA: The significance of multiple, recurrent, and ‘complex’ cardiac myxomas. J Thorac Cardiovasc Surg 1986;91:389–396.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.